Research groups
Yama F Mujadidi
BCA Computer Application , MSc in Information Technology and Software Engineering
Programming and Data Management Director
Automation and Semantic Interoperability in Clinical Trials
Yama F Mujadidi is the Programming and Data Management Director at the Oxford Vaccine Group. In this role, he provides strategic leadership across the Group’s global portfolio of clinical research, with responsibility for data governance, IT infrastructure, programming, and data management systems.
With more than a decade of experience in clinical trials data management and software engineering, he has led the development and validation of electronic data capture systems (MHRA/GxP/FDA compliant), large-scale database infrastructures, and large language models. His expertise spans information governance, clinical trial regulations, and project management, underpinned by a proven ability to lead multidisciplinary technical teams.
Since joining the Oxford Vaccine Group in 2013, Yama has contributed to major international vaccine trials, trained and mentored research teams in the UK and globally, and co-authored numerous publications in high-impact journals. He has also taken a leading role in advancing novel approaches to clinical trial database design and semantic interoperability.
His achievements have been recognised through several awards, including the Fazlur Rahman Khan Award for Excellence in Engineering and Science (2013), the Association for Clinical Data Management’s Individual Excellence Award (2024), and recognition as Best Muslim in STEM by British Muslim (2024).
Beyond Oxford, Yama is an entrepreneur and founder of organisations advancing educational and technological innovation for global health. He is currently pursuing a DPhil at the University of Oxford on automation and semantic interoperability in clinical trials. Alongside his academic and professional commitments, he serves as a delegate with UN Women UK, advocating for the rights of women and children.
Recent publications
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).
Journal article
Li G. et al, (2025), Vaccine, 62
-
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: results from COV-BOOST trial.
Journal article
Janani L. et al, (2025), J Infect
-
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil
Journal article
Costa Clemens SA. et al, (2025), Mayo Clinic Proceedings Innovations Quality and Outcomes, 9
-
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.
Journal article
Feng S. et al, (2025), J Infect, 90
-
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.
Journal article
Conlin K. et al, (2024), Vaccine, 45
-
5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.
Journal article
Qadri F. et al, (2024), Lancet, 404, 1419 - 1429
-
Electronic data capture for large scale typhoid surveillance, household contact tracing, and health utilisation survey: Strategic Typhoid Alliance across Africa and Asia
Preprint
Thindwa D. et al, (2020)